Advocacy Wealth Management Services’s Celldex Therapeutics CLDX Stock Holding History

Advocacy Wealth Management Services’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	$18K	Buy	+33	New	+$11.3K	0.05%	192

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Advocacy Wealth Management Services's CLDX Position: Q3 2013 in Review

Advocacy Wealth Management Services opened a new position in Celldex Therapeutics (CLDX) in Q3 2013: 33 shares worth $18K. The stake represents 0.05% of the portfolio and ranks #192 among its holdings.

150 funds tracked by Wall St. Rank hold CLDX as of Q3 2013.

Advocacy Wealth Management Services held 33 shares of Celldex Therapeutics worth $18K as of Q3 2013.
Celldex Therapeutics was a new Advocacy Wealth Management Services position in Q3 2013.
Celldex Therapeutics made up 0.05% of Advocacy Wealth Management Services's portfolio in Q3 2013, its #192 holding.
150 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2013.

Based on Advocacy Wealth Management Services's 13F filing for Q3 2013, filed 14 Nov 2013.